The types segmentation categorizes the market into singleplex assays, multiplex platforms, and component‑resolved diagnostics (CRD). Singleplex tests target a solitary allergen extract, offering simplicity and low upfront cost, which sustains a steady base of low‑complexity laboratories and point‑of‑care settings. Multiplex platforms, such as microarray or bead‑based systems, simultaneously evaluate dozens of allergen components, delivering higher throughput and richer data for allergists managing poly‑sensitized patients; this segment commands premium pricing and drives growth in specialized allergy centers. Component‑resolved diagnostics isolate individual allergen proteins, enabling precise risk stratification and personalized therapy, increasingly adopted in tertiary care and research institutions. The relative market contribution reflects cost, clinical utility, and adoption barriers: singleplex provides volume stability, multiplex fuels incremental revenue through added value, and CRD expands market depth by addressing complex cases. Together, these type categories shape the overall market dynamics and illustrate the nuanced market taxonomy of Specific IgE Blood Based Allergy Testing.